Re-analysis of cancer vaccine patients with immune-related clinical response criteria (iRRC)

Kentaro Nishida; Takuro Saito; Shinya Urakawa; Masaki Mori; Kazuhiro Kakimi; Yuichiro Doki; Hisashi Wada

Re-analysis of cancer vaccine patients with immune-related clinical response criteria (iRRC)

Kentaro Nishida, Takuro Saito, Shinya Urakawa, Masaki Mori, Kazuhiro Kakimi, Yuichiro Doki, Hisashi Wada

Research output: Contribution to journal › Article › peer-review

Abstract

Anti-tumor responses induced by immunotherapy such as cancer vaccine are presumed to be mediated by induction of cancer-specific immune responses. Therefore, the immune-related response criteria (irRC) have been applied for cancer immunotherapies instead of the Response Evaluation Criteria in Solid Tumors (RECIST). Clinical responses of 91 patients enrolled in our cancer vaccine clinical studies were evaluated using RECIST. In this study, we re-analyzed their clinical responses using irRC. We identified 2 patients whose responses were evaluated as PD by RECIST, but as PR and SD by irRC, respectively. As these 2 patients showed relatively long survival rate, we concluded that irRC was suitable for the assessment of clinical outcomes in cancer immunotherapy.

Original language	English
Pages (from-to)	1466-1468
Number of pages	3
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	45
Issue number	10
Publication status	Published - Oct 2018
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{ccbcde3b422a448a841bc51ffa37cbed,

title = "Re-analysis of cancer vaccine patients with immune-related clinical response criteria (iRRC)",

abstract = "Anti-tumor responses induced by immunotherapy such as cancer vaccine are presumed to be mediated by induction of cancer-specific immune responses. Therefore, the immune-related response criteria (irRC) have been applied for cancer immunotherapies instead of the Response Evaluation Criteria in Solid Tumors (RECIST). Clinical responses of 91 patients enrolled in our cancer vaccine clinical studies were evaluated using RECIST. In this study, we re-analyzed their clinical responses using irRC. We identified 2 patients whose responses were evaluated as PD by RECIST, but as PR and SD by irRC, respectively. As these 2 patients showed relatively long survival rate, we concluded that irRC was suitable for the assessment of clinical outcomes in cancer immunotherapy.",

author = "Kentaro Nishida and Takuro Saito and Shinya Urakawa and Masaki Mori and Kazuhiro Kakimi and Yuichiro Doki and Hisashi Wada",

year = "2018",

month = oct,

language = "English",

volume = "45",

pages = "1466--1468",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "10",

}

TY - JOUR

T1 - Re-analysis of cancer vaccine patients with immune-related clinical response criteria (iRRC)

AU - Nishida, Kentaro

AU - Saito, Takuro

AU - Urakawa, Shinya

AU - Mori, Masaki

AU - Kakimi, Kazuhiro

AU - Doki, Yuichiro

AU - Wada, Hisashi

PY - 2018/10

Y1 - 2018/10

N2 - Anti-tumor responses induced by immunotherapy such as cancer vaccine are presumed to be mediated by induction of cancer-specific immune responses. Therefore, the immune-related response criteria (irRC) have been applied for cancer immunotherapies instead of the Response Evaluation Criteria in Solid Tumors (RECIST). Clinical responses of 91 patients enrolled in our cancer vaccine clinical studies were evaluated using RECIST. In this study, we re-analyzed their clinical responses using irRC. We identified 2 patients whose responses were evaluated as PD by RECIST, but as PR and SD by irRC, respectively. As these 2 patients showed relatively long survival rate, we concluded that irRC was suitable for the assessment of clinical outcomes in cancer immunotherapy.

AB - Anti-tumor responses induced by immunotherapy such as cancer vaccine are presumed to be mediated by induction of cancer-specific immune responses. Therefore, the immune-related response criteria (irRC) have been applied for cancer immunotherapies instead of the Response Evaluation Criteria in Solid Tumors (RECIST). Clinical responses of 91 patients enrolled in our cancer vaccine clinical studies were evaluated using RECIST. In this study, we re-analyzed their clinical responses using irRC. We identified 2 patients whose responses were evaluated as PD by RECIST, but as PR and SD by irRC, respectively. As these 2 patients showed relatively long survival rate, we concluded that irRC was suitable for the assessment of clinical outcomes in cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85055773795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055773795&partnerID=8YFLogxK

M3 - Article

C2 - 30382047

AN - SCOPUS:85055773795

SN - 0385-0684

VL - 45

SP - 1466

EP - 1468

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 10

ER -

Re-analysis of cancer vaccine patients with immune-related clinical response criteria (iRRC)

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this